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Resequencing genes in individuals at extremes of the population distribution constitutes a powerful and
efﬁcient strategy to identify sequence variants associated with complex traits. An excess of sequence var-
iants at one extreme relative to the other that is not due to chance or to population stratiﬁcation constitutes
evidence for genetic association and implies the presence of functionally signiﬁcant sequence variants.
Recently, we reported that non-synonymous sequence variants in Niemann–Pick type C1-like 1 (NPC1L1),
an intestinal cholesterol transporter, were signiﬁcantly more common among individuals with low choles-
terol absorption than in those with high cholesterol absorption. To determine whether sequence variations
identiﬁed in individuals with low cholesterol absorption affect protein function, we performed studies in cul-
tured cells and in families. Expression of the mutant proteins in Chinese hamster ovarian-K1 cells revealed
that a majority (14 of 20) of the variants identiﬁed in low absorbers were associated with very low levels of
NPC1L1 protein. In two extended families, mean cholesterol absorption levels, as measured using stable iso-
topes, were signiﬁcantly lower in family members with the sequence variants than in those without the var-
iant. These data indicate that the excess of sequence variations in individuals with extreme phenotypes
reﬂects an enrichment of functionally signiﬁcant variants. These ﬁndings are consistent with in silico predic-
tions that some sequence variations found in healthy individuals are as deleterious to protein function as
mutations that, in other genes, cause monogenic diseases. Such sequence variations may explain a signiﬁ-
cant fraction of quantitative phenotypic variation in humans.
INTRODUCTION
The uptake of cholesterol from the intestine is a major source
of sterols in humans. Individuals consuming Western diets
ingest 400 mg of dietary cholesterol each day, and an
additional 1000 mg of cholesterol enters the intestine via
the bile (1). On average, 50% of the cholesterol entering
the intestine is absorbed, but the fraction ranges from as
little as 29% to as much as 80% among normal individuals
(2). The wide variation in efﬁciency of cholesterol absorption
is largely attributable to heritable factors (3,4). Plasma levels
of the plant sterols, campesterol and sitosterol, which
provide an index of cholesterol absorption (5), are strongly
correlated between parents and offspring, but not between
spouses (4). The heritability of plasma levels of plant sterols
is signiﬁcantly higher than that of plasma cholesterol levels
(over 80 versus 50%) (3,4). Furthermore, plasma levels of
these plant sterols were signiﬁcantly more highly correlated
between identical twins than between fraternal twins (3,4).
The molecular mechanisms of cholesterol absorption have
not been fully deﬁned, and the factors underlying the wide
variation in fractional cholesterol absorption are poorly under-
stood. Cholesterol is solubilized into mixed micelles by bile
acids in the proximal small intestine and taken up into
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cholesterol acyltransferase. The esteriﬁed cholesterol is then
packaged into large, triglyceride-rich lipoproteins called
chylomicrons, which are secreted from the basolateral surfaces
of enterocytes into the lymphatic system. Variation in the efﬁ-
ciency of any of these processes may contribute to differences
in the efﬁciency of cholesterol absorption.
The uptake of cholesterol into the enterocyte is facilitated
by the polytopic membrane protein, Niemann–Pick type
C1-like 1 (NPC1L1) (6). Mice lacking NPC1L1
(Npc1l1
2/2) have markedly reduced absorption of cholesterol
and plant sterols (6). NPC1L1 is the target of ezetimibe (7),
a drug that blocks cholesterol absorption, and several studies
have reported that sequence variations in NPC1L1 are
associated with responsiveness to ezetimibe (8–11), and
statins (12).
Recently, we examined the contribution of sequence vari-
ation in NPC1L1 to variation in cholesterol absorption in
humans (13). Plasma levels of plant sterols (sitosterol and
campesterol) and cholesterol precursor sterols (lathosterol)
were measured in 3557 individuals from a population-based
study (The Dallas Heart Study) (14). The campesterol:latho-
sterol ratio was used as a surrogate marker of cholesterol
absorption. High rates of cholesterol absorption result in
reduced endogenous cholesterol synthesis, which is reﬂected
in lower plasma levels of lathosterol. Conversely, low absorp-
tion of cholesterol results in increased cholesterol synthesis,
and thus higher lathosterol levels. Thus, a high campesterol:-
lathosterol ratio is indicative of efﬁcient sterol absorption,
whereas a low ratio indicates a low fractional absorption of
sterols (15). A signiﬁcantly higher number of missense
sequence variations in NPC1L1 were found in individuals
with a low fractional cholesterol absorption than in those
with a high fractional cholesterol absorption, whereas the
prevalence of synonymous sequence variants was similar
between the two groups (13). Alleles associated with low
cholesterol absorption were present in 6% of the
African-Americans, and in 2% of whites and Hispanics.
Analysis of the entire Dallas Heart Study revealed that
plasma levels of low-density lipoprotein cholesterol (LDL-C)
were signiﬁcantly lower among African-Americans with
sequence variants associated with low cholesterol absorption
than those without the variants, even after removing those
individuals in the extremes in which the variants were ﬁrst
identiﬁed.
The excess of missense sequence variations among low
absorbers may reﬂect an increased prevalence of defective
NPC1L1 alleles in this group, occult differences in the
genetic ancestries of the high and low absorbers (population
stratiﬁcation) or chance ﬂuctuations in allele frequencies.
Chance ﬂuctuations in allele frequencies were excluded by
replication of the ﬁndings in a second sample of high and
low absorbers drawn from the same population, and analysis
of 2000 ancestry informative SNPs revealed no evidence of
population stratiﬁcation (13). Taken together, these ﬁndings
are consistent with the hypothesis that the non-synonymous
sequence variations we identiﬁed in individuals with low cam-
pesterol:lathosterol ratios impair NPC1L1 function, resulting
in a reduced cholesterol absorption and lower plasma levels
of LDL-C.
To directly evaluate this hypothesis, we examined the
effects of the sequence variations in NPC1L1 on protein
expression in cultured Chinese hamster ovarian (CHO) cells.
Here we show that a large proportion of these sequence vari-
ations destabilized the expressed protein, resulting in signiﬁ-
cantly lower steady-state levels of NPC1L1 in the cells.
These analyses were complemented by studies in the families
of individuals with non-synonymous sequence variations that
were associated with very low NPC1L1 levels in heterologous
cells. We found a signiﬁcant reduction in cholesterol absorp-
tion in the subjects with the NPC1L1 variants compared
with their unaffected family members.
RESULTS
Sequence variations associated with low cholesterol
absorption destabilize NPC1L1
Transfection of constructs expressing wild-type NPC1L1 into
CHO-K1 cells resulted in robust expression of a protein with
an apparent molecular weight of 175 kDa, which is signiﬁ-
cantly greater than that with 145 kDa predicted from the
amino acid sequence (Fig. 1). Treatment of the expressed
protein with PNGase F reduced its apparent molecular
weight to 150 kDa (Supplementary Material, Fig. S1), indi-
cating that NPC1L1 is glycosylated. Endonuclease H did not
reduce the apparent molecular weight of the expressed
protein, indicating that almost all of the NPC1L1 present in
these cells have exited the endoplasmic reticulum and tra-
versed the trans-Golgi. A higher molecular weight band was
also consistently observed in cells transfected with NPC1L1,
but not in mock transfected cells.
Of the 20 alleles found in the low cholesterol absorbers, 14
were associated with markedly reduced expression of NPC1L1
(65–100% decrease) in CHO-K1 cells (Fig. 1). This ﬁnding
suggests that the amino acid changes resulting from these
nucleotide substitutions reduced the stability of the expressed
protein. The reduction in protein expression from these alleles
was consistent across at least three replicate transfections,
using two independent clones for each construct (not
shown). The 14 sequence variants associated with low
NPC1L1 levels were distributed throughout the protein, and
the mechanism(s) by which they perturb protein stability is
not known. Expression levels of three alleles found in high
absorbers were comparable with that of the wild-type protein
(Fig. 1).
Sequence variations I647N and R693C destabilize
NPC1L1 and decrease cholesterol absorption
By screening family members of probands with sequence vari-
ations in NPC1L1, we identiﬁed two large extended pedigrees
in which multiple individuals carried an NPC1L1 allele that
encoded an unstable NPC1L1 protein. In family DHS14, two
individuals were homozygotes for the I647N substitution,
nine were heterozygotes and 26 were homozygotes for the
wild-type allele. The sequence variant showed a statistically
signiﬁcant monotonic gene dosage effect on cholesterol
absorption (Fig. 2) assessed by the area under the curve of
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sterol ratio (P ¼ 3.5   10
25).
The second family, DHS9, included 16 individuals who
were heterozygotes for the R693C substitution and 14 other
family members who were homozygotes for the wild-type
allele. Cholesterol absorption was signiﬁcantly lower in
R693C heterozygotes than in their family members who did
not share this allele (Fig. 3) as determined from the cholesterol
absorption index (P ¼ 0.021) or the campesterol:lathosterol
ratio (P ¼ 0.004).
DISCUSSION
The major ﬁnding of this study is that the majority of the non-
synonymous sequence variations in NPC1L1 identiﬁed by
resequencing individuals with plasma campesterol:lathosterol
levels at the extremes of the population distribution had
severe adverse effects on the expressed protein. Of 20 non-
synonymous sequence variants identiﬁed only in low absor-
bers, 14 markedly reduced expression of recombinant
NPC1L1 when expressed in CHO-K1 cells. Measurements
of cholesterol absorption in two large extended families con-
ﬁrmed that two of these mutations (I647N and R693C) that
were associated with decreased NPC1L1 expression were
also associated with reduced uptake of dietary cholesterol.
Previously, we showed that 6% of African-Americans and
2% of whites and Hispanics carry one of these sequence
variants (13). Therefore, missense sequence variations that
destabilize NPC1L1 and markedly reduce the levels of this
protein are common in the population and lead to reduced
cholesterol absorption and lower levels of plasma LDL-C.
The sequence variations examined in this study were identi-
ﬁed by sequencing NPC1L1 in individuals with campesterol:-
lathosterol ratios in the upper or lower 10% of the population
(13). Comparison of the numbers of sequence variants found
in individuals with trait levels at opposite ends of the distri-
bution provides a simple, unbiased strategy to detect function-
ally signiﬁcant sequence variations. A limitation of this
approach is that some sequence variants may occur in individ-
uals with extreme phenotypes purely by chance. Furthermore,
sequence variants will be enriched at the extremes of the trait
distribution even if they have modest effects on trait levels.
Therefore, further studies are required to assess the functional
consequences of individual sequence variants. As a ﬁrst step
towards functional characterization of the missense sequence
changes in NPC1L1, we expressed the recombinant mutant
proteins in CHO-K1 cells. The ﬁnding that 14 of the 20
amino acid substitutions reduce the levels of NPC1L1
protein expressed suggests that these mutations act primarily
by preventing the formation of a stable protein, rather than
by altering speciﬁc residues required for cholesterol transport.
This ﬁnding is consistent with a large-scale in silico analysis,
which indicated that a majority of mutations responsible for
Figure 1. Expression of wild-type and mutant NPC1L1 in CHO-K1 cells. Plasmids expressing human NPC1L1 were transfected into CHO-K1 cells. After 48 h,
cells were collected and lysed by passage through a 23G needle. Cell membranes were pelleted by ultracentrifugation, resuspended in SDS buffer and size-
fractionated on 8% polyacrylamide gels. Proteins were then transferred to Hybond-C extra nitrocellulose ﬁlters (Amersham Biosciences) and visualized by
immunoblotting with antibodies against hNPC1L1 and calnexin as described in Materials and Methods. The X-ray ﬁlm was scanned using a UMAX PowerLook
III scanner and the intensity of each band was calculated using the computer program Scion Image.
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(16). Since we did not measure protein stability directly, we
cannot exclude the possibility that some of the mutations
decrease protein expression by reducing transcription, RNA
stability or protein translation.
Previously we determined that the sequence variations
found in low absorbers altered residues that showed strong
evolutionary conservation: 12 of the 20 residues were comple-
tely conserved from humans to bony ﬁsh (13). In contrast, the
amino acids altered by sequence variations in the high absor-
bers, or in both groups, were much more variable among
species. Interestingly, the sequence variations that resulted in
unstable proteins altered both highly conserved and poorly
conserved residues. Of the 14 sequence variations associated
with reduced protein expression, eight were in completely
conserved residues. Mutations in the other four completely
conserved residues had little effect on protein levels. These
amino acid substitutions may have more speciﬁc effects on
NPC1L1 function, such as substrate binding or translocation.
Alternatively, their association with low cholesterol absorption
may be spurious.
The sequence variants associated with low cholesterol
absorption were individually too rare to allow meaningful stat-
istical analysis of any single variant in the Dallas Heart Study.
Accordingly, we ascertained family members of probands for
more direct estimates of cholesterol absorption using the
single-isotope-labeled method of Wang et al. (17). In 67 indi-
viduals from two large extended pedigrees, cholesterol absorp-
tion was signiﬁcantly lower in individuals with sequence
variants in NPC1L1 (I647N or R693C) than in those who
did not have these variants. Very similar results were obtained
using the plasma campesterol:lathosterol ratio. This ﬁnding
conﬁrms that the low campesterol:lathosterol ratios in individ-
uals with sequence variants in NPC1L1 reﬂect low fractional
absorption of cholesterol in these individuals.
Pharmacological blockade of cholesterol absorption is an
effective strategy for LDL-lowering. Ezetimibe, the most com-
monly used inhibitor of cholesterol absorption, reduces choles-
terol absorption by binding NPC1L1 (7) and is associated with
reduction in plasma level of LDL-C of 18% (18). Previously,
we found that heterozygotes for the non-synonymous variants
in NPC1L1 identiﬁed in the low campesterol:lathosterol group
had a mean reduction in LDL-C of 9%, which is consistent
with the loss of one NPC1L1 allele. The ﬁnding that a majority
of these sequence variants resulted in very low levels of
NPC1L1 protein in cultured cells is thus congruent with the
magnitude of the reduction in LDL-C observed in vivo.
The cholesterol-lowering efﬁcacy of ezetimibe varies
widely among individuals. Since ezetimibe targets NPC1L1,
variation in NPC1L1 may contribute to individual variation
in responsiveness to ezetimibe. Sequence variations in
NPC1L1 have been associated with responsiveness to ezeti-
mibe in several small studies (8–11). Wang et al. (8)
sequenced the exons of NPC1L1 in non-responders to
ezetimibe and identiﬁed a compound heterozygote for two
non-synonymous sequence variations in the gene. Since
these variants were not identiﬁed in any other individuals,
their relationship to ezetimibe responsiveness could not be
determined. However, one of these variants (I1233N) was
subsequently identiﬁed in an individual with a high campesterol:
lathosterol ratio and is therefore unlikely to be a loss-
of-function allele. These authors also identiﬁed a common
NPC1L1 haplotype that was associated with a greater
Figure 3. Cholesterol absorption and plasma campesterol:lathosterol ratios in
a family segregating the R643C mutation in NPC1L1. For each individual in
the family, the cholesterol absorption index and campesterol:lathosterol ratio
were determined as described in the legend to Figure 2. P-values were calcu-
lated using the Wilcoxon rank sum test. R, arginine; C, cysteine.
Figure 2. Cholesterol absorption and plasma campesterol:lathosterol ratios in
a family segregating the I647N mutation in NPC1L1. Individuals were given
90 mg deuterated cholesterol (25D3, 26D3) in 9 ml medium-chain triglyceride
oil (Novartis), and fasting blood samples were drawn before and 24, 48, 72 and
96 h after cholesterol ingestion. Plasma levels of native cholesterol, hexade-
uterated cholesterol, campesterol and lathosterol were determined using gas-
chromatography and mass spectrometry. The cholesterol absorption index
was calculated as the area under the curve of the deuterated cholesterol:native
cholesterol ratio plotted against time. P-values were calculated using the
Jonckheere–Terpstra test. I, isoleucine; N, asparagines.
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lipidemic subjects (10). Simon et al. (9) identiﬁed a 3-SNP
haplotype that was associated with responsiveness to ezetimibe
in two independent studies: carriers of the minor alleles had a
signiﬁcantly improved response to ezetimibe compared with
non-carriers. One of the SNPs in this haplotype, g.1679C.G
(L272L), was subsequently reported to be associated with
increased response to ezetimibe in two small cohorts of hyper-
lipidemic individuals (11). In each of these studies, none of the
SNPsinNPC1L1wasassociated withbaselinelipidlevels.This
is consistent with our ﬁnding that none of the 32 common
sequence variations in NPC1L1 is associated with baseline
levels of plasma plant sterols, cholesterol or LDL-C (13).
Thus, sequencing individuals with extreme phenotypes and
analysis of common sequence variants at a locus have provided
complementary insights into the genetic architecture of a
complex trait.
Of the 25 000 genes in the human genome, approximately
2000 have been associated with monogenic diseases. Thus,
for the signiﬁcant majority of human genes, no monogenic
disease-causing mutation has been identiﬁed. Yue et al. (16)
noted three possible differences between proteins associated
with monogenic diseases and those that are not. First, the
absence of disease-causing mutations in a gene may reﬂect
intrinsic robustness of the protein to amino acid substitution.
Robustness to mutation is unlikely to account for the lack of
mutations in a large proportion of genes, since nonsense
mutations that totally abolish gene function can arise in any
gene. Alternatively, mutations in a gene may lead to early
fetal death and thus never be recognized as disease-causing.
However, data from knockout mice suggest that only a small
proportion of genes (10–15%) are essential for viability
(19,20). A third possibility is that for some genes, even
mutations that disrupt the function of the expressed protein
do not result in a severe phenotype. The identiﬁcation of
two apparently healthy adults who are homozygous for
mutations that prevent expression of stable NPC1L1 protein
indicates that even chronic deﬁciency of this protein is not
associated with signiﬁcant adverse clinical sequelae. Rather,
mutations that severely impair NPC1L1 function result in
modest, quantitative phenotypic variation. This ﬁnding is con-
sistent with our previous observations with other genes
involved in lipid metabolism (21,22) and may be widely
applicable: several non-synonymous sequence variations
present in apparently healthy individuals appear to be at
least as deleterious to protein function as mutations found in
monogenic diseases (16). These sequence variations may




The study protocol was approved by the Institutional Review
Board of the University of Texas Southwestern Medical
Center at Dallas. Participants in the Dallas Heart Study who
had sequence variations in NPC1L1 associated with low
plasma campesterol:lathosterol ratios were eligible for the
study. Eligible individuals were contacted by telephone, and
two had large extended families in the Dallas area that were
willing to participate in the study.
Measurement of cholesterol absorption
Subjects were seen at home or in the outpatient clinic of the
General Clinical Research Center in Parkland Hospital,
Dallas, TX, USA. Initial blood samples were drawn after an
overnight fast to measure plasma lipoprotein levels and
assess thyroid status and liver function (thyroid-stimulating
hormone, alkaline phosphatase, aspartate and alanine transam-
inase, creatinine and albumin). Two days after the initial blood
draw, a second fasting blood sample was drawn and choles-
terol absorption was measured using a single isotope-labeled
cholesterol tracer (17). Subjects were given 90 mg deuterated
cholesterol (25D3, 26D3) (Medical Isotopes, Inc.) in 9 ml
medium-chain triglyceride oil (Novartis). Blood samples
were drawn 24, 48, 72 and 96 h after cholesterol ingestion.
Plasma was separated by centrifugation at 2500g for 10 min
at 48C, separated into aliquots (200 ml) and stored frozen at
2808C.
Measurements of the isotopic cholesterol in plasma
The amount of deuterated cholesterol in the plasma was
assayed by gas-chromatography mass spectrometry as
described previously (23). The mass spectrometer was run in
selected ion-monitoring mode. Native cholesterol was
measured at m/z 458, and the deuterated cholesterol was
measured at m/z 464. In each sample, the concentration of
deuterated cholesterol was normalized to the concentration
of native cholesterol, and the area under the curve of the deut-
erated cholesterol plotted against time was calculated by
numerical integration using the trapezoidal method, exactly
as described (17).
Construction of pcDNA3.1-hL1 plasmid and hNPC1L1
sequence variant plasmids
Complementary DNA from human intestine was used as
template to amplify hNPC1L1 cDNA (GenBankTM accession
number AY437865) by PCR. Two PCR primers (50-GCTCTA
GACTTGGCTGTTCCTGAGGCCTGGC-30 and 50-CGGGAT
CCTCAGAACTGCCGCCCATTGTTGG-30)w e r es y n t h e s i z e d
with XbaI and BamHI restriction sites at their 50 ends. The
gel-puriﬁed 4 kb PCR products were treated with XbaI
and BamHI and cloned into pcDNA3.1(-) vector (Invitrogen).
Resulting recombinant plasmid was veriﬁed by sequencing
using T7 and gene-speciﬁc primers. Site-directed mutagenesis
was used to generate plasmids expressing 20 mutations ident-
iﬁed in the low cholesterol absorber group and three mutations
found in the high cholesterol absorber group. (13).
Preparation of anti-hNPC1L1 antibody
DNA fragments encoding amino acids 29–253, 404–614 and
860–1100 of NPC1L1 were ampliﬁed by PCR and cloned into
the bacterial expression vector pET-28a(þ) (Novagen). The
expressed proteins were puriﬁed using Ni-NTA beads
Human Molecular Genetics, 2008, Vol. 17, No. 14 2105(Qiagen) and veriﬁed by SDS–PAGE. A mixture of three
puriﬁed peptides was used to immunize rabbits.
Cell culture and preparation of whole-cell membranes
CHO-K1 cells were maintained in a 1:1 mixture of Dulbecco’s
modiﬁed Eagle’s medium and Ham’s F-12 medium containing
100 units/ml penicillin and 100 mg/ml streptomycin sulfate
supplemented with 5% fetal calf serum. Cells were grown at
378Ci n8 – 9 %C O 2. For transfection, CHO-K1 cells were
set up at a density of 7   10
5 cells/10 cm dish on day 0. On
day 1, cells were transfected with 2 mg plasmid DNA/dish
using FuGene 6 (Roche Pharmaceuticals). After 48 h, cells
were collected and whole-cell membrane was prepared.
CHO-K1 cells from each dish were washed twice with PBS
and resuspended in 1 ml TES buffer (20 mM Tris–HCL, 1 mM
EDTA, 250 mM sucrose, pH 7.4). Cells were then passed
through a 23G needle 30 times and centrifuged at 600g for
10 min. The supernatant was collected and centrifuged at
100 000g for 30 min to obtain the membrane pellet. The
pellet was resuspended in loading buffer (3% SDS, 100 mM
NaCl, 10 mM Tris–HCL, 1 mM EDTA, pH 6.8). Protein
concentration was determined using a BCA kit (Pierce
Biotechnology Inc.).
Immunoblot analysis
Thirty micrograms of membrane protein was size-fractionated
on 8% SDS–PAGE gels. Protein was then transferred to
Hybond-C extra nitrocellulose ﬁlters (Amersham Bio-
sciences), immunoblotted using anti-hNPC1L1 serum from
immunized rabbits (1:1000 dilution) and calnexin (Stressgen,
Victoria, BC, Canada), incubated with HRP-conjugated goat
anti-rabbit IgG (Sigma-Aldrich) and visualized using Super-
Signal substrate system (Pierce Biotechnology Inc.).
Statistical methods
The cholesterol absorption index and plasma campesterol:-
lathosterol ratios were compared using the Wilcoxon rank sum
test (to compare two genotype groups) and the Jonckheere–
Terpstra test, a distribution-free test for ordered differences
among classes (to compare three genotype groups).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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